“…However, given that oncocytoma is a benign tumor with excellent prognosis, whereas chRCC is a malignant tumor with metastatic potential, 3 such distinction is critically important for the clinical management of patients. Consequently, when a pathologist is faced with a diagnostic challenge on H&E, he or she relies on a battery of ancillary techniques, 4,5 including immunohistochemistry, 6 electron microscopy, [7][8][9] and cytogenetic analysis, 10,11 to arrive at a definitive diagnosis. Although these techniques have proven to be helpful, none of them are highly specific, and they have overlapping characteristics.…”